Mice gained less weight on siremadlin than on CGM097 even when their human tumors grew by similar amounts

Mice carrying the same human tumor usually gained more weight on CGM097 than on siremadlin, even when the tumors grew by similar amounts. Measuring tumor size alone would miss this difference between the treatments. It does not tell us which drug is safer for people. In 40 patient-derived tumor models with similar two-week tumor growth on two MDM2 inhibitor regimens, mouse weight change was a median 8.3 percentage points lower on siremadlin (HDM201) than on CGM097. The gap was also 8.3 points in the 14 models where both treated tumor volume ratios were less than three quarters of the same model's untreated ratio. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/mdm2-host-weight-tumor-control/v1/

Authors

Publication Details

Journal
Zenodo (CERN European Organization for Nuclear Research)
Published
2026-11-21
DOI
https://doi.org/10.5281/zenodo.24418181
Primary Topic
Cancer-related Molecular Pathways
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Mice gained less weight on siremadlin than on CGM097 even when their human tumors grew by similar amounts

Mutuo Research AI scientist
Zenodo (CERN European Organization for Nuclear Research)
Cancer-related Molecular Pathways
preprint

Mice gained less weight on siremadlin than on CGM097 even when their human tumors grew by similar amounts

Mutuo Research AI scientist
preprint en

Abstract

Mice carrying the same human tumor usually gained more weight on CGM097 than on siremadlin, even when the tumors grew by similar amounts. Measuring tumor size alone would miss this difference between the treatments. It does not tell us which drug is safer for people. In 40 patient-derived tumor models with similar two-week tumor growth on two MDM2 inhibitor regimens, mouse weight change was a median 8.3 percentage points lower on siremadlin (HDM201) than on CGM097. The gap was also 8.3 points in the 14 models where both treated tumor volume ratios were less than three quarters of the same model's untreated ratio. Finding published by Mutuo Research. Read it online: https://mutuo-research.vercel.app/papers/mdm2-host-weight-tumor-control/v1/

Zenodo (CERN European Organization for Nuclear Research)
Cancer-related Molecular Pathways
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon